Regeneron Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Glaxo Wellcome Inc.

Sesen Bio, Inc.

Ohana Biosciences, Inc.

Aventis Pharma S.a.

Glaxosmithkline LLC

Albumedix Limited

Eleven Biotherapeutics, Inc.

Innate Biotherapeutics, LLC

Eric Steven Furfine

Daniel B Dix

Kenneth S Graham

Kelly Frye

Michael Robin Hale

Andrew Spaltenstein

Ray Camphausen

Christopher Todd Baker

Ronald George Sherrill

Vicente Samano

Roger D Tung

Istvan Kaldor

Barry George Shearer

Jeffrey Alan Oplinger

Ricardo Attar

Sharon T Cload

Marco Gottardis

David Fabrizio

Michael L Gosselin

Tracy S Mitchell

Joanna F Swain

Joan Carboni

H Nicholas Marsh

Francois Maltais

Jeffrey Charles Way

Thomas M Barnes

Ranjan Mukherjee

Stephen Colin Price

George D Yancopoulos

John D Mendlein

Clarence Webster Andrews, Iii

John Franklin Miller

Edward Patrick Garvey

Paul E Morin

Irvith M Carvajal

Simeon I Taylor

Michael March Schmidt

Timothy A Stammers

Alison Tisdale

Matthew John Traylor

Wieslaw Mieczylaw Kazmierski

Christopher D Thanos

Neil E Stahl

Edwin L Madison

Eric C Bigham

Kathleen Seyb

Jesse M Cedarbaum

Mikhail Popkov

David V Erbe

Vanessa Soros

Jon Loren Collins

Wayne Carl Schairer

Gregory Thomas Lowen

Felipe A Navarrete Solano

Robin David Wilkes

Ashley Nicholas Jarvis

Michael Stephen Brieger

Kimberly Tipton

Marie-Christine Bissery

Gabriel Oscar Reznik

Hua Miao

James Michael Siedlecki

Jocelyn Holash

Ifat Rubin-Bejerano

Patricia Vrignaud

Marielle Chiron-Blondel

Grigorios Zarbis-Papastoitsis

John James Kane

Grant E Blouse

Tom Knudsen

Amy Jada Andreucci

Zuzana Dostalova

Isabelle Sansal-Castellano

Jan Kristian Jensen

Emil Oldenburg

Christine René Schar

Agnieszka Jendroszek

Arzu Sandikci

Jim Mcguire

Shyam Rajan Iyer

Natacha Le Moan

Ranjan Mukerjee

Brajesh Kumar

Fran&ccedil;ois Maltais

Marco M Gottardis

Ricardo M Attar

Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

Modified urokinase-type plasminogen activator polypeptides and methods of use

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

VEGF antagonist formulations suitable for intravitreal administration

Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.

Complement factor I-related compositions and methods

The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.

ß-1,6-glucan therapeutic antibody conjugates

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

Interleukin-6 (IL-6) antagonists are provided that are specific for binding to site II of IL-6. Methods of using such inhibitors to treat IL-6 related diseases, e.g., disease of the eye such as diabetic macular edema are disclosed.

IL-6 antagonists and uses thereof

Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

IL-6 antibodies

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-bindingFn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

Serum albumin binding molecules

The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins

The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.

Variant serum albumin with improved half-life and other properties

The disclosure provides, inter alia, methods of improving sperm function and related methods of fertilization, together with preparations of activated or potentiated sperm. The disclosure additionally provides articles of manufacture suitable for performing the methods provided by the invention. The methods provided by the disclosure, in some embodiments entail energy depletion with subsequent staged reintroduction of different energy sources.

Compositions and methods for enhancing sperm function

Methods for promoting fertilization

Growing community of inventors

Durham, NC, United States of America

Eric Steven Furfine